Pharming Group (NASDAQ:PHAR – Get Free Report) will be posting its quarterly earnings results before the market opens on Wednesday, May 8th. Analysts expect Pharming Group to post earnings of $0.01 per share for the quarter.
Pharming Group (NASDAQ:PHAR – Get Free Report) last posted its earnings results on Thursday, March 14th. The company reported ($0.03) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.08). The firm had revenue of $81.20 million for the quarter, compared to analysts’ expectations of $71.83 million. Pharming Group had a negative return on equity of 4.53% and a negative net margin of 4.13%. On average, analysts expect Pharming Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Pharming Group Trading Up 0.0 %
PHAR opened at $10.00 on Monday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.33 and a current ratio of 4.06. The business has a 50 day moving average of $10.70 and a 200-day moving average of $11.36. Pharming Group has a 52 week low of $9.27 and a 52 week high of $16.71.
Wall Street Analyst Weigh In
Read Our Latest Report on Pharming Group
About Pharming Group
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Read More
- Five stocks we like better than Pharming Group
- What is the S&P/TSX Index?
- Brinker International Heats Up on Spicy Earnings Beat and Raise
- 3 Small Caps With Big Return Potential
- Eli Lilly Gains on the GLP-1 Weight Loss Phenomenon
- Using the MarketBeat Dividend Tax Calculator
- Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.